Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shelly Leeds Richter

Obstetrics & Gynecology Houston, TX Medical Doctor

NPI 1861494171 CMS profile 220482

7900 Fannin St, Suite 4000, Houston, TX 77054

Open in the dashboard

General payments

$3,824

147 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shelly Leeds Richter of Houston, TX is reported in the CMS Open Payments database as having received $3,824 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $658 25
2024 General $343 17
2023 General $426 19
2022 General $475 27
2021 General $346 19
2020 General $498 18
2019 General $1,079 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shelly Leeds Richter
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Shelly Leeds Richter were reported at $658. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Shelly Leeds Richter Obstetrics & Gynecology median Middle half National median
2019 $1,079 $172 $62–$391 $163
2020 $498 $94 $36–$222 $114
2021 $346 $136 $42–$369 $132
2022 $475 $160 $50–$433 $149
2023 $426 $169 $56–$423 $160
2024 $343 $152 $50–$371 $164
2025 $658 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Exeltis, USA Inc. $840 12 payments
  2. Renovia Inc $467 10 payments
  3. AbbVie, Inc. $394 22 payments
  4. Amgen Inc. $187 10 payments
  5. Hologic, LLC $177 9 payments
  6. Medtronic, Inc. $176 2 payments
  7. Astellas Pharma US Inc $162 8 payments
  8. CooperSurgical, Inc. $137 6 payments
  9. Pfizer Inc. $132 9 payments
  10. Myovant Sciences Inc. $117 5 payments
  11. Other $1,036 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,309 145 payments
  2. Consulting Fee $500 1 payment
  3. Entertainment $16 1 payment
Products named General payments · program years 2019–2025
  1. SLYND $624 2 payments
  2. Leva Pelvic Floor Trainer $467 10 payments
  3. LO LOESTRIN FE $340 18 payments
  4. EVENITY $187 10 payments
  5. MYFEMBREE $178 8 payments
  6. VENASEAL $154 1 payment
  7. Veozah $131 6 payments
  8. ORIAHNN $123 8 payments
  9. PREMARIN $103 8 payments
  10. ZURZUVAE $97 5 payments
  11. Other $1,960 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,569

Median for Obstetrics & Gynecology: 65

Drug cost

$125,864

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

57.1%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Premarin Estrogens, Conjugated Brand 142 $50,256
Estradiol (Twice Weekly) Estradiol Brand 201 $21,134
Estradiol Generic 265 $16,074
Estradiol (Once Weekly) Estradiol Brand 76 $6,724
Lyllana Estradiol Brand 50 $5,070
Estradiol-Norethindrone Acetat Estradiol/Norethindrone Acet Brand 46 $3,949
Yuvafem Estradiol Brand 21 $3,599
Dotti Estradiol Brand 25 $2,644
Progesterone Progesterone, Micronized Brand 138 $2,572
Raloxifene Hcl Generic 55 $2,017

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$82,527

Medicare's payments for the services billed

Medicare patients

503

Average age 72

Services billed

1,631

503 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 41%
Osteoporosis 24%
Ischemic heart disease 17%
Diabetes 12%
Cancer 11%
Depression 11%
Chronic kidney disease 9%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $45
$45 — —
ABRYSVO
  • PFIZER INC. $40
$40 — —
NUVESSA
  • Exeltis, USA Inc. $24
$24 — —
SLYND
  • Exeltis, USA Inc. $23
$23 — —
Wegovy
  • Novo Nordisk Inc $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record